A guide for patients with established cardiovascular disease preparing for their first cardiology or telehealth visit. Covers records to gather, questions to ask, medications to list, and what the SELECT trial means for your treatment plan.
A guide to secondary prevention of cardiovascular events in adults with established CVD, covering antiplatelet therapy, statins, GLP-1 receptor agonists, blood pressure control, and lifestyle interventions with citations to major trials and guidelines.
A complete annual evaluation checklist for male hypogonadism: lab panels, symptom scoring, safety monitoring, dose adjustments, and guideline-based targets from the Endocrine Society and AUA.
A guide to identifying, evaluating, and enrolling in clinical trials for male hypogonadism, with diagnostic criteria, eligibility frameworks, and links to primary literature.
A clinical guide to male hypogonadism diagnosis, management, and the specific signs that warrant a second medical opinion. prepared by the HealthRX.com Editorial Team.
Learn exactly when testosterone replacement therapy stops working, how clinicians define treatment failure in male hypogonadism, and what to do next. Evidence-based guidance with cited trials and Endocrine Society criteria.
An evidence-based annual evaluation checklist for menopause-related weight gain, covering labs, body composition, HRT considerations, and GLP-1 options with specific doses, trials, and guideline citations.
Learn how partners and family members can actively support someone living with NAFLD or MASLD through lifestyle changes, emotional support, and shared habits that improve liver health outcomes.
A guide to identifying, evaluating, and enrolling in obesity clinical trials. Covers eligibility criteria, major active trials, GLP-1 and combination therapies, and step-by-step enrollment guidance for adults with BMI ≥30.
A board-reviewed annual evaluation checklist for obstructive sleep apnea (OSA): AHI targets, CPAP adherence review, weight management, comorbidity screening, and updated 2024 treatment options including tirzepatide.
A guide to choosing between low-dose HRT, combined oral contraceptives, and non-hormonal therapies for perimenopause, based on current NAMS, Endocrine Society, and ACOG guidelines.
Secondary hypogonadism is frequently overlooked or confused with primary testicular failure, depression, or aging. Learn the red-flag lab patterns, commonly missed causes, and fertility-preserving treatment options including enclomiphene and hCG.
A guide to finding, evaluating, and enrolling in Type 2 Diabetes clinical trials. Covers eligibility criteria, key active trials, GLP-1 and SGLT2 options, and step-by-step enrollment guidance.
A overview of male hypogonadism prevalence worldwide, secular trends, risk factors, and what the latest epidemiological data mean for diagnosis and treatment.
A guide to how menopause-related weight gain affects Black, Hispanic, Asian, and white women differently, with primary epidemiology, guideline recommendations, and treatment considerations by race and ethnicity.
A look at the biological mechanisms researchers believe drive NAFLD/MASLD progression, including lipid overload, mitochondrial dysfunction, the gut-liver axis, and genetic risk, with an honest account of what is established versus still under investigation.
NAFLD affects roughly 38% of adults worldwide under the newer MASLD criteria. This evidence-based overview covers global prevalence data, regional variation, risk factor trends, and what the 2023 nomenclature change means for clinicians and patients.
A comprehensive clinical history of PCOS treatment from the 1930s to today, covering surgical, hormonal, metabolic, and emerging therapies, with primary-source citations throughout.
How common is secondary hypogonadism worldwide? Current epidemiology, rising prevalence drivers, regional differences, and what clinical guidelines say about screening and diagnosis.
A clinical deep-dive into rare and atypical presentations of secondary hypogonadism, including genetic causes, drug-induced forms, functional variants, and diagnostic pitfalls. Reviewed by board-certified physicians.
Secondary hypogonadism carries measurable economic costs through lost wages, healthcare utilization, and long-term comorbidities. This evidence-based review covers the financial burden on patients, payers, and society, and flags where precise figures require independent verification.
A clinical history of type 2 diabetes treatment, from early dietary restriction through metformin, sulfonylureas, TZDs, incretin-based drugs, SGLT2 inhibitors, and dual-agonist therapy, with the evidence hierarchy and open questions readers should carry into any current treatment discussion.
A guide to dapagliflozin (Farxiga) hair loss and skin changes, including genital mycotic infections, rash incidence from clinical trials, and what to do if symptoms appear.
Evidence-based natural remedies and lifestyle treatments for PCOS, including diet, exercise, inositol, berberine, and when to consider medications. prepared by the HealthRX.com Editorial Team.
Peptide fatigue is real. Learn why GLP-1 and peptide therapies drain B12, sodium, potassium, and magnesium, and what doses actually fix it, backed by clinical evidence.
A deep dive into the evidence for GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) improving menopause-related brain fog, memory, and cognitive function, including mechanisms, trial data, and clinical guidance.
Testosterone is not just a male hormone. Learn how it affects libido, energy, bone density, and mood in women, what happens during menopause, and what the evidence says about testosterone therapy for women.
A guide to dulaglutide safety in adolescents with type 2 diabetes, covering FDA approval status, trial data, dosing, growth monitoring, and contraindications for ages 12, 17.
A guide to discontinuing Trulicity (dulaglutide), covering tapering strategies, rebound hyperglycemia risk, medication transitions, and what to monitor after your last dose.
Dulaglutide (Trulicity) is not FDA-approved for NAFLD or MASLD, but trial data suggest it reduces hepatic fat and liver enzymes in patients with type 2 diabetes. Learn what the evidence shows, how it is dosed, and who may benefit.
A guide to using dulaglutide (Trulicity) for prediabetes: off-label rationale, dosing, trial evidence from REWIND and AWARD studies, side effects, and how to talk to your doctor.
A guide to dulaglutide (Trulicity) safety in adults aged 65 and older, covering renal function, falls risk, GI tolerability, drug interactions, cardiovascular evidence from REWIND, and deprescribing thresholds.
A guide to how state Medicaid programs generally handle Trulicity (dulaglutide) coverage, prior authorization, step therapy, and appeals for type 2 diabetes and, in some states, weight management. State rules vary and require direct verification.
A comprehensive clinical guide to monitoring dulaglutide (Trulicity) in pediatric patients under age 12, covering FDA labeling, dosing, growth surveillance, safety labs, and GI adverse effects.
A clinician-level guide to dulaglutide (Trulicity) pharmacogenomics, covering GLP-1R variants, TCF7L2 genotype effects, metabolic enzyme polymorphisms, cardiovascular outcomes by ancestry, and how genetic testing might one day personalize GLP-1 therapy.
A guide to dulaglutide (Trulicity) use during pregnancy and breastfeeding, covering FDA labeling, animal data, GLP-1 receptor biology, and evidence-based alternatives for managing type 2 diabetes in reproductive-age women.
A clinician-level guide to switching between dulaglutide (Trulicity) and other GLP-1 receptor agonists, covering dose conversion, washout timing, cardiovascular evidence from REWIND, and practical injection guidance.
A clinical deep-dive into how dulaglutide (Trulicity) changes appetite, food cravings, and eating behavior in type 2 diabetes. Includes trial data, mechanism, dose effects, and practical management.
A clinician-level review of dulaglutide (Trulicity) use in patients with autoimmune conditions, covering thyroid disease, IBD, lupus, RA, and safety signals from REWIND and post-marketing data.
A deep-dive into dulaglutide's long-term cardiovascular effects, anchored in the REWIND trial and supporting literature. Learn what a 12% MACE reduction means clinically, who benefits most, and how dulaglutide compares to other GLP-1 receptor agonists.
A primary-literature analysis of dulaglutide's effect on cognition, brain health, and dementia risk in type 2 diabetes, including REWIND trial data and mechanistic research.
A GRADE-level analysis of dulaglutide (Trulicity) clinical evidence, covering cardiovascular outcomes, glycemic efficacy, weight, safety, and how the data stacks up for shared decision-making in type 2 diabetes.
A week-by-week guide to dulaglutide (Trulicity) in your first month: side effects, blood sugar changes, dosing milestones, and what the evidence from REWIND and AWARD trials actually shows.
Evidence-based strategies to preserve lean mass while on Trulicity (dulaglutide), including resistance training protocols, protein targets, and monitoring checkpoints reviewed by HealthRX.com physicians.
A guide to using dulaglutide (Trulicity) after bariatric surgery, covering pharmacokinetics, dosing, evidence from REWIND and other trials, and practical prescribing considerations for post-bariatric patients with type 2 diabetes.
When and how to safely restart dulaglutide (Trulicity) after acute illness, hospitalization, or GI upset. Evidence-based dosing protocols, monitoring parameters, and red flags from the REWIND trial and ADA guidelines.
A guide to dutasteride (Avodart) safety in men aged 65 and older, covering renal function, falls risk, drug interactions, cardiovascular signals, and deprescribing criteria.
Avodart (dutasteride) info for ages 50-64: half-life, DHT suppression, REDUCE trial prostate cancer data, sexual side effects, and drug interaction risks.
A week-by-week guide to the first 30 days on dutasteride (Avodart) for BPH and hair loss. Covers DHT suppression timelines, shedding phases, side effects, and what your lab work should show.
Why dutasteride (Avodart) stops working for BPH or hair loss, what the evidence says, and the clinical steps to take when you hit a plateau.
A deep dive into empagliflozin (Jardiance) and its known effects on hair, skin, and related dermatologic conditions, including genital mycotic infections, urinary changes, and rare rash reports.
A clinical evidence review of enclomiphene citrate use in adolescents aged 12 to 17: what adult and pediatric-adjacent data show, what is unstudied, and the monitoring and consent standards this age group requires.
A guide to monitoring enclomiphene citrate therapy in men aged 30, 49, covering lab schedules, dose adjustments, safety endpoints, and when to stop treatment.
A clinical guide to Anthem (Elevance Health) coverage, prior authorization criteria, step therapy requirements, and appeal strategies for enclomiphene citrate prescriptions.
A clinical and insurance guide to Cigna coverage, prior authorization, step therapy, and appeal strategies for enclomiphene citrate prescriptions. prepared by the HealthRX.com Editorial Team.
A comprehensive clinical review of enclomiphene citrate for secondary hypogonadism: how it works, what the trial data show, dosing protocols, side effects, and who qualifies for treatment.
A comprehensive look at the origins, chemistry, clinical trials, and regulatory path of enclomiphene citrate, the trans-isomer of clomiphene with a distinct mechanism for treating secondary hypogonadism while preserving fertility.
A state-by-state guide to Medicaid coverage, prior authorization, step therapy, and appeal strategies for enclomiphene citrate prescribed for secondary hypogonadism.
A guide to enclomiphene citrate off-label uses, covering secondary hypogonadism, male infertility, PCOS, and more, with evidence grades, named trials, doses, and primary-source citations.
A guide to monitoring enclomiphene citrate in adults aged 50, 64, covering lab schedules, cardiovascular risk, polypharmacy, and dose adjustments for secondary hypogonadism.